T regulatory cells (Tregs) play a key role in modulating T cell responses. Clinical trials showed that Tregs modulate graftversus-host disease (GvHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, their ability to mediate anti-leukemic activity (graft-versus-leukemia [GvL] ) is largely unknown. Enforced interleukin-10 (IL-10) expression converts human CD4 + T cells into T regulatory type 1 (Tr1)-like (CD4 ) cells that suppress effector T cells in vitro and xenoGvHD in humanized mouse models. In the present study, we show that CD4
IL-10 cells mediate antileukemic effects in vitro and in vivo in a human leukocyte antigen (HLA) class I-dependent but antigen-independent manner. The cytotoxicity mediated by CD4
IL-10 cells is granzyme B (GzB) dependent, is specific for CD13 + target cells, and requires CD54 and CD112 expression on primary leukemic target blasts. CD4
IL-10 cells adoptively transferred in humanized mouse models directly mediate anti-tumor and anti-leukemic effects. In addition, when co-transferred with peripheral blood mononuclear cells (PBMCs), CD4
IL-10 cells contribute to the GvL activity but suppress xenoGvHD mediated by the PBMCs. These findings provide for the first time a strong rationale for CD4 cell immunotherapy to prevent GvHD and promote GvL in allo-HSCT for myeloid malignancies.
INTRODUCTION
T regulatory cells (Tregs) promote and maintain immunological tolerance. Among Tregs, FOXP3
+ Tregs 1 and the T regulatory type 1 (Tr1) cells have been extensively investigated.
2 Tr1 cells are induced in the periphery upon chronic antigen (Ag) stimulation in the presence of interleukin 10 (IL-10); 2 co-express CD49b and LAG-3; 3 and secrete IL-10, transforming growth factor b (TGF-b), variable amounts of interferon (IFN)-g, and low IL-2, IL-4, and IL-17. [2] [3] [4] Tr1 cells suppress T cell responses via the secretion of IL-10 and TGF-b, 2, 5 and the specific killing of myeloid cells via granzyme B (GzB). 6 Ag-specific Tr1 cells can be generated in vitro in the presence of IL-10 or tolerogenic DC-10. 7 In the past decade, much effort has been devoted to develop methods for the in vitro induction and/or expansion of Tregs suitable for cell therapy. 8 Treg-based cell therapy has been extensively tested in preclinical models of graft-versus-host disease (GvHD), [9] [10] [11] [12] and proofof-principle clinical trials in allogeneic hematopoietic stem cell transplantation (allo-HSCT) have demonstrated the safety of Tregbased cell therapy. [13] [14] [15] [16] [17] Freshly isolated 14, 15, 17 or in-vitro-expanded polyclonal CD25 + Tregs 13, 16 were infused after allo-HSCT for hematological malignancies to prevent GvHD. In these studies, a reduction in GvHD severity was observed as compared with historical controls. Furthermore, it has been reported that in CD25 + Tregtreated patients, the cumulative incidence of relapse was significantly lower than in controls. 17 In a clinical trial aimed at promoting immune reconstitution in the absence of severe GvHD, we demonstrated the safety and feasibility of Tr1 cell infusion in hematological cancer patients undergoing haploidentical HSCT. 18 Host-specific
IL-10-anergized donor T cells (IL-10 donor lymphocyte infusion
[DLI]), containing Tr1 cells, were infused in the absence of immunosuppression in a small cohort of patients. Results demonstrated that after IL-10 DLI infusion, only moderate GvHD was observed and a tolerance signature was achieved. Furthermore, the treatment accelerated immune reconstitution and correlated with long-lasting disease remission. 18 A major difference between the CD25 + Tregbased trials and the IL-10 DLI trial is that, in the former, a pool of polyclonal non-Ag-specific cells was administered, whereas in the latter, anergized donor-derived T cells, which contain host-specific Tr1 cells, were infused.
Despite the significant progress in establishing in vitro protocols to induce alloantigen-specific IL-10-anergized T cells for Tr1-based immunotherapy, the resulting population still contains a large proportion of effector T cells that could potentially limit the in vivo efficacy of Tr1 cells. 19 To overcome this limitation, we developed a method to generate a selected population of IL-10-producing Tr1 cells by lentiviral vector (LV)-mediated human IL-10 gene transfer. IL-10-engineered CD4 + (CD4 IL-10 ) cells display a cytokine profile and phenotype super-imposable to bona fide Tr1 cells, suppress T cell responses, lyse myeloid cell lines in vitro, and prevent xenoGvHD in vivo. 20 In the present study, we investigate the anti-leukemic and anti-tumor activity of polyclonal and alloantigen-specific CD4 IL-10 cells in vitro and in vivo. We demonstrate that CD4
IL-10 cells generated with an LV encoding for human IL-10 and DNGFR (LV-IL-10) specifically kill myeloid leukemic cell lines in a human leukocyte Ag (HLA) class I-dependent, but Ag-independent, manner. CD4
IL-10 cells kill also primary myeloid blasts in vitro, and this anti-leukemic activity is dependent on CD13, CD54, and CD112 expression on target cells. Furthermore, CD4 IL-10 cells have a direct anti-tumor and antileukemic effect, and collaborate with allogeneic peripheral blood mononuclear cells (PBMCs) to mediate graft-versus-leukemia (GvL), while inhibiting xenoGvHD in vivo. These data strongly support the use of CD4 Tr1 cells as immunotherapy to prevent GvHD and promote GvL in allo-HSCT for myeloid malignancies. Figure S1A ). Transduction efficiency of CD4 + CD45RO À T cells was on average 51.3%, and the percentage of cell recovery after selection of DNGFR-expressing cells reflected the percentage of transduced cells (57% ± 19%, mean ± SD, n = 8; Table S1 ). After selection, in vitro expansion of polyclonal CD4 IL-10 cells cultured with feeder mixture was lower compared with control cells transduced with LV-GFP/DNGFR (CD4 DNGFR ) (Table S1 ). CD4 IL-10 cells generated with LV-IL-10/DNGFR recapitulated the Tr1 cell phenotype, as previously described for LV-IL-10/GFP. 20 Figure 1B ).
RESULTS

Polyclonal
Consistently, in 4-day co-culture experiments, CD4 IL-10 cells eliminated CD14 cells, U932, ALL-CM, and THP-1, but not BV-173 or K562 cell lines ( Figures 1C and S3 ).
Overall, these data demonstrate that CD4 IL-10 cells kill specifically myeloid cells and myeloid leukemic cell lines. Alloantigen-specific LV-10-transduced T (allo-CD4 IL-10 ) cells were generated by stimulation of naive CD4 + T cells with allo-mDCs and transduced upon secondary stimulation (Figure 2A ). Transduction efficiency was on average 52.5%, and after selection of DNGFR-expressing cells, the percentage of cell recovery (45% ± 9.9%, mean ± SD, n = 10) reflected that of transduced cells (Table S2) . Allo-CD4
IL-10 and allo-CD4 DNGFR cells equally expanded in vitro when cultured with feeder mixture ( Figure 2B ; Table S2 ). In contrast, allo-CD4 IL-10 cells re-stimulated with allo-mDCs proliferated significantly less compared with allo-CD4 DNGFR cells ( Figure 2C ), despite reported; n = 4 independent donors for CD4 and CD4 DNGFR cells against ALL-CM and U937 cell lines, tested in two independent experiments, and n = 2 for CD4 similar levels of IFN-g production ( Figure 2D ). As expected, allo-CD4 IL-10 cells spontaneously released significantly higher IL-10 amounts compared with allo-CD4 DNGFR cells. Importantly, upon allo-mDC stimulation, IL-10 production by allo-specific CD4
IL-10 cells increased and was significantly higher compared with that of control cells ( Figure 2E ). Allo-CD4 IL-10 and allo-CD4 DNGFR cells had similar low proliferative capacity and IFN-g production in response to third-party Ags (third-party mDCs) ( Figures 2C and  2D ), but allo-CD4 IL-10 cells produced higher levels of IL-10 (Figure 2E) . Moreover, allo-CD4 IL-10 , but not allo-CD4 DNGFR , cells efficiently suppressed the proliferation of allo-specific T cell lines activated with allo-mDCs, but not with third-party mDC ( Figure 2F Figure 2G ).
These results show that enforced IL-10 expression in allo-specific CD4 + T cells promotes their conversion into Tr1-like suppressor cells able to kill myeloid cell lines. The U937, THP-1, and ALL-CM cell lines that were killed by CD4 cells expressed CD54, HLA class I, CD58, CD155, and CD112, whereas K562 and Daudi cell lines that were not killed by CD4 cells were HLA class I-negative and expressed CD54 and variable levels of CD58, CD155, or CD112 ( Figure S4 ). The BV173 cell line, which was not killed by CD4
IL-10 cells, expressed HLA class I and CD58, but not CD54 and CD155, and it was CD112 dim ( Figure S4 ). These findings suggest that CD4 IL-10 -mediated killing requires HLA We next tested the ability of CD4 IL-10 cells to kill primary blasts isolated from patients with acute myeloid leukemia (AML blasts) at diagnosis and classified according to the French-American-British (FAB) subtypes and World Health Organization (WHO) categories (Table 1). As negative controls, we used primary non-myeloid blasts isolated from patients with acute lymphoblastic leukemia (ALL blasts) at diagnosis (Table 1) 
CD54
+ CD112 + AML blasts from patients Leu #1, Leu #2, Leu #6, and Leu #8, but they did not kill AML blasts from patients Leu 3, Leu 4, and Leu #5, which were CD13 À and CD54 À . Moreover, CD4 IL-10 cells did not eliminate CD13 + CD54 + CD112 À AML blasts from patient Leu #7 ( Figure 5B ). Interestingly, CD4 IL-10 cells eliminated blasts expressing CD13, CD54, and CD112 from one of the three ALL patients (Leu #10) ( Figure 5B).
Although a small cohort of patients was tested, these data suggest that CD4 We tested the anti-leukemic activity of CD4 IL-10 cells in vivo in four different humanized models: the subcutaneous myeloid sarcoma, the extra-medullary THP-1 myeloid tumor, 24 Next, we assessed the anti-leukemic activity of CD4 IL-10 cells on a THP-1 myeloid tumor. 24 In this model, mice injected with THP-1 cell lines developed cysts in the liver starting from week 2, and at week 4 the liver weight was 3.7 ± 1.7 g (mean ± SD, n = 12; Figure 6B ). Injection of PBMCs 2 weeks after THP-1 cell infusion prevented tumor growth as demonstrated by the reduced liver weight (2.7 ± 0.3 g, mean ± SD, n = 3; Figure 6B ) and the reduced number of liver cysts and liver-infiltrating THP-1 cells ( Figure S6 ). Adoptive transfer of CD4 IL-10 cells 2 weeks after THP-1 injection significantly inhibited tumor growth (liver weight: 2.1 ± 0.9 g, mean ± SD, n = 8; Figure 6B ). In addition, CD4 -treated mice had a lower number of liver cyst and liver-infiltrating THP-1 cells ( Figure S6 ). In contrast, no differences were observed in tumor development in CD4 DNGFR -treated versus untreated THP-1-injected mice (liver weight: 3.9 ± 0.8 g, mean ± SD, n = 7, and 3.7 ± 1.7 g, mean ± SD, n = 12, respectively; Figures 6B and S6).
We next evaluated whether CD4 IL-10 cells mediate anti-leukemic effects in an ALL-CM leukemia model. NSG mice were sub-lethally irradiated, injected with ALL-CM cell lines, and after 3 days with allogeneic PBMCs, CD4 IL-10 cells, or CD4 DNGFR cells ( Figure 6C ).
Adoptive transfer of CD4 IL-10 cells significantly delayed leukemia progression, whereas treatment with CD4 DNGFR cells did not. Importantly, the leukemia progression in CD4 -injected mice was not significantly different from that observed with PBMC-injected mice ( Figure 6C ).
We previously showed that adoptive transfer of CD4 IL-10 cells prevents xenoGvHD mediated by human CD4 + T cells in non-obese Cr release. Mean ± SEM of n = 3 independent donors performed in triplicates is reported. Analysis was performed in one experiment.
www.moleculartherapy.org diabetic-severe combined immunodeficiency (NOD-SCID) mice. 20 Here, we tested the effects of CD4 IL-10 cells in irradiated NSG mice injected with ALL-CM cell lines and PBMCs. In this setting, PBMCs protected mice from leukemia, but induced a lethal xenoGvHD (Figure 7 ). Mice injected with PBMCs in the absence of ALL-CM developed xenoGvHD with a slower kinetic compared with mice injected with ALL-CM+PBMCs, and as expected, they did not develop leukemia ( Figure 7 ). This different kinetic could be because of the presence of allogeneic ALL-CM, which may provide an additional signal for PBMC activation in vivo. Interestingly, adoptive transfer of CD4 IL-10 cells together with PBMCs mediated protection from leukemia in 60% of the mice and prevented development of xenoGvHD in the mice (Figure 7) . Using a bioluminescence analysis, we observed that CD4 IL-10 cells infused in combination with PBMCs contributed in preventing leukemia development ( Figures 8A-8C ) and at the same time completely blocked lethal xenoGvHD mediated by PBMCs ( Figure 8D ).
Overall, these findings demonstrate that CD4 IL-10 cells have direct antitumor and anti-leukemic effects in vivo in humanized mouse models. In addition, CD4 IL-10 cells and PBMCs have a cumulative GvL effect, but CD4
IL-10 cells prevent xenoGvHD induced by allogeneic PBMCs. 
DISCUSSION
We previously reported that enforced expression of IL-10 confers a Tr1-like phenotype and function to human CD4 + T cells, including killing of myeloid cells. 20 In this study, we show that Tr1 (CD4 IL-10 ) cells generated with a novel bidirectional LV encoding for human IL-10 and DNGFR, as a clinical-grade marker gene, upregulate the expression of CD18, CD2, and CD226, and secrete GzB. CD4
IL-10 cells acquire cytotoxic activity restricted to myeloid cells, including myeloid leukemic cell lines and, of note, primary myeloid leukemic blasts. We demonstrate that alloantigen-specific Tr1 cells obtained by LV-10 transduction of allogeneic T cells (allo-CD4 IL-10 cells) are also able to kill myeloid cells in an Ag-independent manner. The myeloid-specific killing mediated by CD4 IL-10 is HLA class I dependent; however, HLA-class I expression on target CD13 + primary blasts is not sufficient to promote the CD4 -mediated cytotoxicity, which also requires stable CD54-mediated adhesion and activation via CD226. In humanized mouse models, CD4
IL-10 cells mediate potent direct antitumor and anti-leukemic effects, prevent xenoGvHD mediated by allogeneic effector cells, and contribute to the GvL effect.
Previous studies indicated that Tregs can kill effector T cells through a granzyme-dependent mechanism and that this cytotoxicity contributes to their suppressive function. 25, 26 In addition, we showed that Tr1 cells eliminate myeloid, but not lymphoid, cells. 6 In the present study, we demonstrate that the cytotoxic activity of CD4 IL-10 cells is specifically directed against myeloid leukemic cells and myeloid blasts. The correlation between the expression of the myeloid marker CD13 on target cells and the ability of CD4 IL-10 cells to eliminate primary leukemic blasts suggests that CD13 expression determines the myeloid specificity of CD4 IL-10 cell-mediated cytotoxicity. Killing of primary blasts by CD4 IL-10 cells also correlates with CD54 expression, showing the importance of adhesion between target cells and CD4 IL-10 cells for effective cytolysis. CD54 on myeloid blasts allows stable and prolonged interaction with LFA-1 on CD4 IL-10 cells, which enables the targetdirected secretion of lytic granules containing GzB. In addition, similar to what was described for NK-mediated lysis of AML blasts, 27 the interaction between CD112 on myeloid leukemic target blasts and CD226 on CD4
IL-10 cells is required for CD4 IL-10 cell activation. Because CD226 is involved in the downstream signaling cascade of LFA-1, 28 we speculate that CD112/CD226 interaction contributes to the stabilization of CD4 -target cell conjugates that triggers CD4 IL-10 cell degranulation. CD226-mediated activation of T cells is inhibited by T cell immunoreceptor with Ig and ITIM domains (TIGIT), 29 another receptor for CD112 and CD155. 30 TIGIT binds to CD155 with higher affinity than CD226 and inhibits the cytotoxic activity and IFN-g production by NK cells. 31, 32 However, primary blasts express CD155 at lower levels than CD112, 27, 33 and CD4 IL-10 -mediated lysis does not correlate with CD155 expression. Thus, although CD4
IL-10 cells express both TIGIT (data not shown) and CD226, activation via CD226/ CD112 is dominant over the inhibitory signal mediated by TIGIT/ CD155. Overall, our findings indicate that CD13, CD54, and CD112 expression on leukemic blasts may be used as biomarkers predictive of the anti-leukemic effect mediated by CD4 IL-10 cells. IL-10 cells eliminate myeloid leukemia in a TCR-independent, but HLA class I-dependent, manner suggests their possible use to limit, and possibly to overcome, leukemia relapse caused by the loss of not-shared HLA alleles after allo-HSCT. [34] [35] [36] Recognition of host alloantigens by donor T lymphocytes is responsible for GvHD after allo-HSCT, a major cause of transplant-related morbidity and mortality. Donor T cells also recognize alloantigens on leukemic cells, thus mediating a beneficial GvL. 37 Prevention and treatment of GvHD currently relies on depletion of T cells from the graft or on general immunosuppression, which, however, abrogates the GvL effect, increasing the incidence of leukemia relapse. 38 Establishing a regimen that prevents GvHD without affecting GvL represents a key challenge in allo-HSCT treatment of hematological malignancies. (4) contribute to the GvL activity, but suppress the xenoGvHD mediated by the PBMCs in vivo. These findings pave the way for the use of CD4 IL-10 cell immunotherapy to prevent GvHD and promote GvL in allo-HSCT for myeloid malignancies. 
MATERIALS AND METHODS
Subjects
All protocols were approved by the Institutional Review Board, and samples were collected under written informed consent according to the Declaration of Helsinki. AML and ALL patient characteristics referred to the San Raffaele Hematology and Bone Marrow Transplantation Unit at diagnosis are listed in Table 1 .
Cell Preparation and Cell Lines
PBMCs were prepared by centrifugation over Ficoll-Hypaque gradients. CD4 + T cells were purified with the CD4 T cell isolation kit www.moleculartherapy.org (Miltenyi Biotec), resulting in purity of >95%. CD4 + T cells were then depleted of CD45RO + cells using anti-CD45RO-coupled magnetic beads and LD-negative selection columns (Miltenyi Biotech). The proportion of CD4 + CD45RA + in the selected population was consistently >90%. CD14 + and CD3 + T cells were purified by positive selection with CD14 + and CD3 + Microbeads (Miltenyi Biotec), respectively, with a resulting purity of >95%. U937 (monocytic cell line), K562 (erythroleukemic cell line), BV-173 (a pre-B lymphoblastic leukemia), 23 Daudi (B lymphoblastic cell line), and THP-1
(myelomonocytic leukemia) cell lines were obtained from the ATCC. The ALL-CM cell line derived from a CML patient suffering from a Philadelphia chromosome-positive lymphoid blast crisis was kindly provided by Dr. A. Bondanza. To generate b 2 m-deficient ALL-CM and U937 cell lines, cells were nucleofected by Amaxa 4D Nucleofector System with X-unit (Lonza) using the EP100 program. In brief, 3 Â 10 5 cells were re-suspended in a solution containing 20 mL of SF solution (Lonza) and 3 mL of pre-mixed Cas9 plasmid (500 ng) and the specific B2M guide #18 CRISPR plasmid (5 0 -GAGT AGCGCGAGCACAGCTA-3 0 cut in B2M exon 1, 250 ng). After nucleofection, cells were expanded in culture. To generate ALL-CM-expressing luciferase (ALL-CM Luc ), the ALL-CM cell line was transduced with an LV encoding for phosphoglycerate kinase (PGK)-luciferase (kindly provided by Prof. Ferrari G.) at an MOI of 50 and expanded in X-VIVO15 medium with 5% human serum (BioWhittaker-Lonza), 100 U/mL penicillin-streptomycin (BioWhittaker). All cell lines were routinely tested for mycoplasma contamination.
Plasmid Construction
The coding sequence of human IL-10 was excised from pH15C (ATCC 68192), and the 549 bp fragment was cloned into the multiple cloning site of pBluKSM (Invitrogen) to obtain pBluKSM-human interleukin-10 (hIL-10). A fragment of 555 bp was obtained by excision of hIL-10 from pBluKSM-hIL-10 and ligation to 1074.1071.hPGK.GFP.WPRE.mhCMV.dNGFR.SV40PA (here named LV-DNGFR), to obtain LV-IL-10/DNGFR. The presence of the bidirectional promoter (human PGK promoter plus minimal core element of the cytomegalovirus (CMV) promoter in the opposite direction) allows co-expression of the two transgenes. The sequence of LV-IL-10/DNGFR was verified by pyrosequencing (Primm).
Vector Production and Titration
VSV-G-pseudotyped third generation bidirectional lentiviral vectors (bdLVs) were produced by Ca 3 PO 4 transient four-plasmid co-transfection into 293T cells and concentrated by ultracentrifugation as described previously. 20 Titer was estimated by limiting dilution, vector particles were measured by HIV-1 Gag p24 Ag immune capture (NEN Life Science Products), and vector infectivity was calculated as the ratio between titer and particle. Titers ranged from 5 Â 10 8 to 6 Â 10 9 transducing units/mL, and infectivity from 5 Â 10 4 to 10 5 transducing units/ng p24.
Dendritic Cell Differentiation
Peripheral blood CD14 + monocytes were positively selected using CD14 + Microbeads (Miltenyi Biotec) according to the manufacturer's instructions. Cells were cultured in RPMI 1640 (Lonza) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin/streptomycin (Lonza), 2 mM L-glutamine (Lonza), at 37 C in the presence of 10 ng/mL recombinant human (rh) IL-4 (R&D Systems) and 100 ng/mL recombinant human granulocytemacrophage colony-stimulating factor (rhGM-CSF) (Genzyme) for 5 days. To generate mature dendritic cells (mDCs), on day 5 we matured cells with 1 mg/mL lipopolysaccharide (LPS; Sigma) for an additional 2 days. At day 7, DCs were collected, phenotypically analyzed, and used to stimulate T cells. The purity and maturation state of DCs were checked by flow cytometry to determine expression of CD1a, CD14, CD86, CD83, and HLA-DR.
Transduction of Human CD4 + T Cells
Polyclonal CD4-transduced cells were obtained as previously described. 20 CD4 + DNGFR + cells were beads-sorted using CD271 + Microbeads (Miltenyi Biotec) and expanded in X-VIVO15 medium with 5% human serum (BioWhittaker-Lonza), 100 U/mL penicillinstreptomycin (BioWhittaker), and 50 U/mL rhIL-2 (PROLEUKIN; Novartis). To generate alloantigen-specific transduced cells, we stimulated naive CD4 + T cells (10 6 /well) with allogeneic mDCs (10 5 /well).
At days 7 and 10, medium was replaced by fresh medium supplemented with 25 U/mL rhIL-2. At day 14, cells were collected, washed, and 24 hr after the secondary stimulation with the same allo-mDCs used for priming, cells were transduced with LV-GFP/DNGFR (allo-CD4 DNGFR ) or LV-IL-10/DNGFR (allo-CD4 IL-10 ) at an MOI of 20. Transduced CD4 + DNGFR + T cells were purified and stimulated every 2 weeks with allogeneic feeder mixture as previously described. 20 Purity of selected cells was consistently greater than 95%. Allo-CD4 DNGFR and allo-CD4 IL-10 cells after two to three feeder www.moleculartherapy.org mixture expansions were used to perform in vitro and in vivo experiments.
Cytokine Determination
In vitro experiments were performed with CD4 DNGFR and CD4 For the detection of FOXP3 (clone 259D; BioLegend) after surface staining, cells were fixed, permeabilized, and stained with the Foxp3 staining Buffer Set according to the manufacturer's instructions (eBioscience). For the expression of GzB (clone MHGB04; Invitrogen) after surface staining, cells were fixed, permeabilized, and stained with the BD Cytofix/Cytoperm Kit according to the manufacturer's instructions (catalog no. 554714; BioLegend). To evaluate human chimerism in peripheral blood of treated NSG mice, we co-stained cells with anti-human CD45 (clone HI30; BioLegend), anti-human CD3 (clone SK7; BD Biosciences), anti-human CD33 (clone AC104.3E3; Miltenyi Biotec), anti-CD271 (clone ME20.4; BioLegend), and anti-murine CD45 (clone 30F11; BD Biosciences) mAbs. Samples were acquired using a FACS Canto II flow cytometer (Becton Dickinson), and data were analyzed with FCS express (De Novo Software). Quadrant markers were set to unstained controls.
Cytotoxicity Assays
CD4
DNGFR and CD4 IL-10 cell degranulation was evaluated in CD107a flow cytometric assay, and their cytotoxic activity was analyzed in a standard 51 Cr-release assay, as described by Magnani et al. 6 Cytotoxicity of transduced cells was also analyzed in co-culture experiments. In brief, target and effector cells were plated in a 1:1 ratio for 3 days. At the end of co-culture, cells were harvested and surviving cells were counted and analyzed by FACS. In some experiments, anti-HLA class I (clone W6/32; BioLegend), anti-HLA class II (anti-HLA-DR, -DQ, -DR; BioLegend), and isotype control (IgG2a,k; BD Pharmingen) mAbs, or the GzB inhibitor (Benzyloxycarbonyl-Ala-AlaAsp-chlormethylkethone) (Z-AAD-CMK) (Sigma) were added at the indicated concentrations. Elimination index (EI) was calculated as 1 À (number of targets that remained in the co-culture with CD4 IL-10 per number of targets that remained in the co-culture with CD4 DNGFR ).
Mice NSG female mice were purchased from Charles-River Italia. All mice were fed standard laboratory diet and maintained under standard laboratory conditions free of specific pathogens. All animal care procedures were performed according to protocols approved by the OSR Institutional Animal Care and Use Committee (IACUC protocol 488), following the 3R principles (replacement, reduction and refinement) and the Decreto Legislativo #116 dated January 27 th , 1992, from the Italian Parliament.
Humanized Mouse Models
In all experiments 6-to 8-week-old female NSG mice were used.
Subcutaneous ALL-CM Tumor Model
On day 0 mice were subcutaneously injected with ALL-CM cells (2 Â 10 6 ) and on day 3 with PBMCs (2 Â 10 6 ), CD4 IL-10 cells, or CD4 DNGFR (1 Â 10 6 ) cells. Sarcoma growth was monitored at least three times per week, and moribund mice were euthanized for ethical reasons.
THP-1 Tumor Model
On day 0 mice were intravenously injected with THP-1 cells (2 Â 10 6 ) and on day 14 with PBMCs (2 Â 10 6 ), CD4 IL-10 cells, or CD4
DNGFR
(1 Â 10 6 ) cells. Survival and weight loss were monitored at least three times per week as previously described. 21 At week 4, mice were euthanized to analyze human cells in the liver.
Graft-versus-Leukemia Model, ALL-CM Leukemia Model
On day 0 mice received total body irradiation with a single dose of 175-200 cGy from a linear accelerator according to the weight of the mice and were intravenously injected with ALL-CM cells (5 Â 10 6 ) and on day 3 with PBMCs (5 Â 10 6 ), CD4 IL-10 cells, or CD4 DNGFR (2.5 Â 10 6 ) cells. Survival and weight loss were monitored at least three times per week as previously described 21 and were euthanized for ethical reasons. At weekly intervals mice were bled and human chimerism was determined by calculating the frequency of human CD45 + cells within the total lymphocyte population.
Graft-versus-Leukemia and GvHD Model
On day 0 mice received total body irradiation as above and were intravenously injected with ALL-CM cells (5 Â 10 6 ). On day 3 mice were injected with PBMCs (5 Â 10 6 ) alone or in combination with CD4 IL-10 or CD4 DNGFR (2.5 Â 10 6 ) cells. As control, irradiated mice were intravenously injected on day 3 with PBMCs (5 Â 10 6 cells/mouse). Survival, weight loss, and human chimerism were monitored as above.
Bioluminescence Image Acquisition
Small-animal bioluminescence imaging (BLI) was performed using the IVIS Spectrum CT System (Perkin Elmer). The system is composed of a low-noise, back-thinned, back-illuminated charge-coupled device (CCD) camera cooled at À90 C with a quantum efficiency in the visible range above 85%. Each mouse received an intraperitoneal injection of 150 mg luciferin/kg body weight 10 min before BLI. During image acquisition, the animals were kept at 37 C and under gaseous anesthesia (2%-3% isoflurane and 1 L/min oxygen). Dynamic BLI was performed by acquiring a set of images every 2 min from 10 to 20 min after luciferin injection to detect the highest BLI signal. The images were obtained using the following settings: exposure time = auto, binning = 8, f = 1, and field of view = 13 cm (field C). Dark images were acquired before and then subtracted to bioluminescence images; no emission filters were used during BLI acquisitions.
Bioluminescence Image Analysis
BLI image analysis was performed by placing a region of interest (ROI) over the mouse and by measuring the total flux (photons/ seconds) within the ROI. Images were acquired and analyzed using Living Image 4.5 (Perkin Elmer).
Statistical Analysis
The number of replicates per mouse to be used for each experiment has been estimated in order to get a power in identifying the variables considered >90% alpha error = 0 and on the basis of previous experience with the animal strains and animal models. No randomization was applied to animal studies, and investigators were not blinded. All data produced were analyzed by statistical methods chosen according to number and distribution of the determinations and variance and variation of the experimental groups. All the results were tested for normal distribution of the variables analyzed, and parametric or non-parametric test will be used accordingly. All these statistical analyses were performed with the consulting assistance of the University Centre for Statistics in the Biomedical Sciences (CUSSB) at the San Raffaele University, Milan. Statistical analyses on the functional data were performed using a MannWhitney U test for non-parametric data and a two-way analysis of variance test. One-way ANOVA tests and Bonferroni's multiple comparisons were used to analyze the data from the in vivo experiments. The p values less than 0.05 were considered significant. Statistic calculations were performed with the Prism program 5.0 (GraphPad Software). CD4
IL-10 cells that did not display a cytokine profile (IL-10/IL-4 ratio > 4) and suppressive activity were not included in the analysis.
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